WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--In Phase IIb study results presented by Merck & Co., Inc., anacetrapib (formerly known as MK-0859), its investigational selective cholesteryl ester transfer protein (CETP) inhibitor, significantly reduced LDL-cholesterol (LDL-C) and Apolipoprotein B (Apo B) and increased HDL-cholesterol (HDL-C) and Apolipoprotein A-1 (Apo A-1) both as monotherapy and in combination with atorvastatin 20 mg compared to placebo in patients with dyslipidemia. These results were presented today at the 16th International Symposium on Drugs Affecting Lipid Metabolism (DALM).
